Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is significantly increased during successful immunotherapy across human malignancies. In this study, we describe the generation and zirconium-89 (89 Zr) radiolabeling of monoclonal antibody (mAb) clones that specifically recognize human CD103 for non-invasive immune positron-emission tomography (PET) imaging of T cell infiltration as potential biomarker for effective anticancer immune responses. Experimental design First, to determine the feasibility of anti-CD103 immuno-PET to visualize CD103-positive cells at physiologically and clinically relevant target densities, we developed an 89 Zr-anti-murine CD103 PET tracer. Healthy, non-tumor bearing C57...
The use of cell-based therapies as a living drug have gained considerable attention for the treatmen...
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy whe...
Purpose: Recent clinical successes in the use of chimeric antigen receptor (CAR) T cell therapy has ...
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is sign...
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is sign...
The ability to non-invasively monitor tumor-infiltrating T cells in vivo could provide a powerful to...
BackgroundBispecific antibodies redirecting T cells to the tumor obtain increasing interest as poten...
There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor infiltrat...
The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of noninvas...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
Purpose: Immunomonitoring of chimeric antigen receptor (CAR) T cells relies primarily on their qua...
[177Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunothera...
AMG 110, a bispecific T cell engager (BITE) antibody construct, induces T cell-mediated cancer cell ...
Pancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore, additional effe...
Positron emission tomography (PET) is an attractive imaging tool to localize and quantify tracer bio...
The use of cell-based therapies as a living drug have gained considerable attention for the treatmen...
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy whe...
Purpose: Recent clinical successes in the use of chimeric antigen receptor (CAR) T cell therapy has ...
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is sign...
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is sign...
The ability to non-invasively monitor tumor-infiltrating T cells in vivo could provide a powerful to...
BackgroundBispecific antibodies redirecting T cells to the tumor obtain increasing interest as poten...
There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor infiltrat...
The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of noninvas...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
Purpose: Immunomonitoring of chimeric antigen receptor (CAR) T cells relies primarily on their qua...
[177Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunothera...
AMG 110, a bispecific T cell engager (BITE) antibody construct, induces T cell-mediated cancer cell ...
Pancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore, additional effe...
Positron emission tomography (PET) is an attractive imaging tool to localize and quantify tracer bio...
The use of cell-based therapies as a living drug have gained considerable attention for the treatmen...
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy whe...
Purpose: Recent clinical successes in the use of chimeric antigen receptor (CAR) T cell therapy has ...